MDXG (MiMedx Group) E10: $-0.06 (As of Mar. 2026)


MDXG MiMedx Group Inc MDXG
57 GF Score
Price $3.82
GF Value $6.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group E10?

MiMedx Group MDXG -0.39% 57 E10 is $-0.06 as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

MiMedx Group's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.070. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.06 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 20.60% per year. During the past 5 years, the average E10 Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of MiMedx Group was 50.00% per year. The lowest was -115.40% per year. And the median was 5.00% per year.

As of today (2026-06-26), MiMedx Group's current stock price is $3.815. MiMedx Group's E10 for the quarter that ended in Mar. 2026 was $-0.06. MiMedx Group's Shiller PE Ratio of today is .


MiMedx Group  (NAS:MDXG) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


MiMedx Group E10 Related Terms


MiMedx Group E10 Historical Data

* Premium members only.

The historical data trend for MiMedx Group's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiMedx Group E10 Chart

MiMedx Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.10 -0.06 -0.04 -0.05

MiMedx Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.05 -0.04 -0.05 -0.06

MDXG vs ASMB, AGMB, TRAX: E10 Comparison

For the Biotechnology subindustry, MiMedx Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiMedx Group Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Shiller PE Ratio falls into.


MDXG
57GF Score
MiMedx Group Inc MDXG
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiMedx Group E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MiMedx Group's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.07/330.2130*330.2130
=-0.070

Current CPI (Mar. 2026) = 330.2130.

MiMedx Group Quarterly Data

per share eps CPI Adj_EPS
201606 0.020 241.018 0.027
201609 0.030 241.428 0.041
201612 -0.057 241.432 -0.078
201703 0.040 243.801 0.054
201706 0.070 244.955 0.094
201709 0.150 246.819 0.201
201712 0.300 246.524 0.402
201803 0.040 249.554 0.053
201806 0.020 251.989 0.026
201809 -0.002 252.439 -0.003
201812 -0.340 251.233 -0.447
201903 -0.120 254.202 -0.156
201906 -0.160 256.143 -0.206
201909 0.110 256.759 0.141
201912 -0.070 256.974 -0.090
202003 -0.040 258.115 -0.051
202006 -0.080 257.797 -0.102
202009 -0.480 260.280 -0.609
202012 -0.170 260.474 -0.216
202103 -0.090 264.877 -0.112
202106 -0.030 271.696 -0.036
202109 -0.040 274.310 -0.048
202112 0.010 278.802 0.012
202203 -0.110 287.504 -0.126
202206 -0.110 296.311 -0.123
202209 -0.090 296.808 -0.100
202212 -0.020 296.797 -0.022
202303 -0.060 301.836 -0.066
202306 0.000 305.109 0.000
202309 0.060 307.789 0.064
202312 0.322 306.746 0.347
202403 0.060 312.332 0.063
202406 0.120 314.175 0.126
202409 0.050 315.301 0.052
202412 0.050 315.605 0.052
202503 0.050 319.799 0.052
202506 0.060 322.561 0.061
202509 0.110 324.800 0.112
202512 0.100 324.054 0.102
202603 -0.070 330.213 -0.070

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.06 mean?
MiMedx Group (MDXG) has a E10 of $-0.06 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on MiMedx Group and its competitors.
Is MiMedx Group's E10 too high?
MiMedx Group's current E10 is $-0.06. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's E10 compare to ASMB and AGMB?
MiMedx Group's E10 of $-0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on MiMedx Group and its competitors. MiMedx Group's current E10 is $-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.82 — trading 45.2% below its estimated fair value. The current E10 is $-0.06. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For MiMedx Group (MDXG), the current E10 is $-0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $3.82 is trading 45.2% below its estimated GF Value™ of $6.96. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • E10: $-0.06
  • GF Value™: $6.96 vs. price of $3.82 (45.2% below fair value)
  • GF Score™: 57/100 with 2 warning signs

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$6.96
GF Value